Persistent luminescence nanoparticles for cancer theranostics application

被引:0
作者
Nian Liu
Xiao Chen
Xia Sun
Xiaolian Sun
Junpeng Shi
机构
[1] Xiamen University,Xiamen Cardiovascular Hospital
[2] China Pharmaceutical University,State Key Laboratory of Natural Medicines, Key Laboratory of Drug Quality Control and Pharmacovigilance, Department of Pharmaceutical Analysis
[3] Technical University of Munich,Department of Chemistry
[4] Ludwig-Maximilians-Universität München,Medizinische Klinik Und Poliklinik IV
[5] Chinese Academy of Sciences,Key Laboratory of Design and Assembly of Functional Nanostructures, Fujian Institute of Research On the Structure of Matter
[6] Chinese Academy of Sciences,Department of Translational Medicine, Xiamen Institute of Rare Earth Materials
来源
Journal of Nanobiotechnology | / 19卷
关键词
Persistent luminescence nanoparticles; Synthesis; Surface modification; PersL imaging; Multiple excitation sources; Theranostics;
D O I
暂无
中图分类号
学科分类号
摘要
Persistent luminescence nanoparticles (PLNPs) are unique optical materials that emit afterglow luminescence after ceasing excitation. They exhibit unexpected advantages for in vivo optical imaging of tumors, such as autofluorescence-free, high sensitivity, high penetration depth, and multiple excitation sources (UV light, LED, NIR laser, X-ray, and radiopharmaceuticals). Besides, by incorporating other functional molecules, such as photosensitizers, photothermal agents, or therapeutic drugs, PLNPs are also widely used in persistent luminescence (PersL) imaging-guided tumor therapy. In this review, we first summarize the recent developments in the synthesis and surface functionalization of PLNPs, as well as their toxicity studies. We then discuss the in vivo PersL imaging and multimodal imaging from different excitation sources. Furthermore, we highlight PLNPs-based cancer theranostics applications, such as fluorescence-guided surgery, photothermal therapy, photodynamic therapy, drug/gene delivery and combined therapy. Finally, future prospects and challenges of PLNPs in the research of translational medicine are also discussed.
引用
收藏
相关论文
共 801 条
[1]  
Lozano R(2012)Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2095-2128
[2]  
Naghavi M(2017)Cancer nanomedicine: progress, challenges and opportunities Nat Rev Cancer 17 20-37
[3]  
Foreman K(2017)Towards clinically translatable in vivo nanodiagnostics Nat Rev Mater 2 17014-3852
[4]  
Lim S(2017)Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment Chem Soc Rev 46 3830-1198
[5]  
Shibuya K(2019)Nanoparticles-mediated combination therapies for cancer treatment Adv Ther 2 1900076-2524
[6]  
Aboyans V(2019)An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites J Pharm Pharmacol 71 1185-2136
[7]  
Abraham J(2016)Chemically engineered persistent luminescence nanoprobes for bioimaging Theranostics 6 2488-620
[8]  
Adair T(2009)Persistent luminescence beats the afterglow: 400 years of persistent luminescence Electrochem Soc Interface 18 42-1170
[9]  
Aggarwal R(2016)Long persistent phosphors—from fundamentals to applications Chem Soc Rev 45 2090-544
[10]  
Ahn S(2019)Persistent luminescence instead of phosphorescence: history, mechanism, and perspective J Lumin 205 581-3466